Scandinavian ChemoTech Q2 2024: Initial comments - Redeye

Redeye provides its initial comments on the Q2 2024 report from Scandinavian Chemotech, which was mostly in line with estimates. Sales came in at SEK1.7m, aligned with expectations and the communicated order flow. Costs were influenced by one-offs, partly explaining the miss on profitability.

Länk till analysen i sin helhet: https://www.redeye.se/research/1029176/scandinavian-chemotech-q2-2024-initial-comments?utm_source=finwire&utm_medium=RSS